Compagnie Lombard Odier SCmA Grows Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Compagnie Lombard Odier SCmA grew its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 31.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,565 shares of the pharmaceutical company's stock after acquiring an additional 3,000 shares during the period. Compagnie Lombard Odier SCmA's holdings in Vertex Pharmaceuticals were worth $6,092,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of VRTX. Norges Bank bought a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at $1,374,948,000. GAMMA Investing LLC increased its position in Vertex Pharmaceuticals by 60,572.3% in the first quarter. GAMMA Investing LLC now owns 2,425,070 shares of the pharmaceutical company's stock worth $1,175,722,000 after purchasing an additional 2,421,073 shares during the last quarter. Parnassus Investments LLC bought a new stake in Vertex Pharmaceuticals in the fourth quarter worth $731,283,000. Capital World Investors increased its position in Vertex Pharmaceuticals by 5.7% in the fourth quarter. Capital World Investors now owns 28,325,695 shares of the pharmaceutical company's stock worth $11,406,667,000 after purchasing an additional 1,514,993 shares during the last quarter. Finally, Capital Research Global Investors increased its position in Vertex Pharmaceuticals by 15.8% in the fourth quarter. Capital Research Global Investors now owns 10,428,951 shares of the pharmaceutical company's stock worth $4,199,713,000 after purchasing an additional 1,426,746 shares during the last quarter. Institutional investors own 90.96% of the company's stock.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX stock traded up $7.62 during mid-day trading on Thursday, hitting $460.06. 1,074,482 shares of the stock were exchanged, compared to its average volume of 1,416,995. The stock's fifty day simple moving average is $463.17 and its two-hundred day simple moving average is $460.26. The stock has a market capitalization of $118.14 billion, a price-to-earnings ratio of -209.12, a P/E/G ratio of 2.11 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). The company had revenue of $2.77 billion during the quarter, compared to analysts' expectations of $2.85 billion. Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. The business's revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $4.76 EPS. On average, analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. The Goldman Sachs Group reissued a "buy" rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Cantor Fitzgerald restated an "overweight" rating and set a $535.00 target price on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Scotiabank dropped their target price on Vertex Pharmaceuticals from $450.00 to $442.00 and set a "sector perform" rating on the stock in a research note on Tuesday, May 6th. Royal Bank of Canada boosted their target price on Vertex Pharmaceuticals from $420.00 to $423.00 and gave the stock a "sector perform" rating in a research note on Tuesday, May 6th. Finally, Morgan Stanley boosted their target price on Vertex Pharmaceuticals from $462.00 to $464.00 and gave the stock an "equal weight" rating in a research note on Tuesday, May 6th. Fourteen analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $515.04.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.